Advanced Medical Solutions Group (LSE:AMS), one of the larger healthcare companies on the FTSE AIM All Share Index, has spent much of 2026 at the centre of Takeover activity. After confirming approaches from more than one suitor, the company agreed to a takeover by US adhesives group H.B. Fuller valued at around £715 million. The development suggests the surgical and wound care specialist may be nearing the end of its life as a standalone listed company.
What the Company Does
Advanced Medical Solutions develops and manufactures products for the surgical, wound care and wound closure markets. Its portfolio includes tissue adhesives, sutures, haemostats and advanced wound dressings, sold to hospitals and healthcare providers around the world, both under its own brands and through partners. The UK-based group has built its Business through a combination of in-house innovation and acquisitions, giving it a presence in several international markets.
Latest Developments
The takeover story unfolded in stages. In April 2026, the company confirmed it had received a bid approach from private Investment firm TA Associates. The following month, it confirmed a separate takeover approach from H.B. Fuller, and the company later confirmed that it was in takeover talks with H.B. Fuller and that the deadline under UK takeover rules for a firm offer had been extended. The company subsequently agreed to the roughly £715 million Acquisition by H.B. Fuller.
As is required during an offer period, AMS published details of its issued Share Capital for the purposes of takeover disclosures, stating that it had 220.8 million ordinary shares in issue. The precise timetable for completion, including Shareholder and regulatory approvals, was not set out at the time of writing and should be checked in the company's own announcements.
Financial Picture
Alongside the takeover, AMS has continued to report on trading. A half-year 2026 trading update was followed by interim results showing Revenue of £115.2 million for the first half of 2026. That period saw order delays and a de-stocking strategy in Europe affect performance, although group revenue and adjusted profit rose. Detailed profit and Dividend figures were not available at the time of writing. AMS has historically paid dividends, but any future payments are likely to be shaped by the terms of the takeover.
Sector and index Context
UK-listed medical technology companies have attracted interest from Overseas Trade buyers and private investment, often because their valuations on public markets have lagged those of comparable businesses elsewhere. The interest in AMS from two separate bidders fits that pattern. If the deal completes, the FTSE AIM All Share Index would lose one of its more substantial healthcare constituents, continuing a trend of AIM companies being taken private or absorbed by larger groups.
Key Risks
The main risk for shareholders is that the deal fails to complete, for example if required approvals are not obtained, which could lead to a fall in the share price towards pre-bid levels. Until completion, the company remains exposed to its usual operational risks, including order timing, destocking by distributors, regulatory requirements for medical devices and competition in surgical consumables.
What to Watch Next
Investors will be watching for the scheme document or offer documentation, the dates of any court and shareholder meetings, regulatory clearances and the expected timing of completion and delisting from AIM. Any further comment from TA Associates, or any other interested party, would also be closely followed.






Please wait processing your request...